|Awarded On||February 18, 2015|
|Title||Epigenetics in Medulloblastoma Development and Therapeutics|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Vidya Gopalakrishnan|
|Cancer Sites||Brain and Other Nervous System, Childhood and Adolescent|
Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Although significant improvements have been made in 5-year survival rates in the past decade, survivors continue to be at substantial risk for recurrence and metastasis. Unfortunately the outcome for these patients is dismal as there are no therapeutic options available at this time. An incomplete knowledge of tumor biology and molecules that drive tumorigenesis has significantly hampered efforts to develop new treatments. The current focus on tumor genetics by many groups has yielded only a few druggable targets. In contrast, abnormalities in the tumor cell chromatin architecture or epigenome can be reversed pharmacologically...